Recovery of behavioral symptoms in hemi-parkinsonian rhesus monkeys through combined gene and stem cell therapy

Zhou, Yan; Sun, Maosheng; Zhang, Dongliang; Yan, Min; He, Zhaoyi; Wang, Wenju; Wang, Wanpu; Lu, Shuaiyao

doi:10.1016/j.jcyt.2013.01.007

Cited by 34 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A progressive recovery was observed in the group transplanted with neuronal-primed ASCs only, and, coherently, the TH+ immunoreactive cells counted in the SN were 15 % of the intact side. TH+ cells rose to 30 % of the intact side in the combined group, thus providing evidence that about 30 % of TH+ cells in the SN is enough to induce stable recovery (Zhou et al, 2013). Xu and collaborators (2010) performed autografts of NSCs derived from BMSCs and transfected or not with human gene coding for TH in CdN and SN (1.5-3 × 10 6 cells per site) of hemiparkinsonian monkeys 6 weeks following 1-month intoxication with intracarotid perfusion of MPTP (1.2 mg kg −1 ; Xu et al, 2010).…”

Section: Impact Of the Immune Status Of The Host Brainmentioning

confidence: 90%

“…However, even if those studies are necessary for testing different types of transplant before investigation in a larger number of animals, reporting clinical motor score has been very well documented for many parkinsonian models and should be an imperative standard, considering that those investigations require sacrifice of NHPs. From the remaining studies, about half of them reported in vivo functional outcome following graft in addition to behavioral outcome assessing clinical motor symptoms; however, some studies just reported qualitatively those functional changes (Xu et al, 2010;Emborg et al, 2013a;Sundberg et al, 2013;Zhou et al, 2013). Surprisingly, and even so non-motor symptoms are recognized as having a great impact on quality of life in PD patients (Simuni and Sethi, 2008), no graft study using the NHP MPTP model to date has reported effects on non-motor symptoms.…”

Section: Impact Of the Immune Status Of The Host Brainmentioning

confidence: 99%

See 1 more Smart Citation

Transplantation in the nonhuman primate MPTP model of Parkinson's disease: update and perspectives

Wianny

Vezoli

2017

Primate Biol.

View full text Add to dashboard Cite

Abstract. In order to calibrate stem cell exploitation for cellular therapy in neurodegenerative diseases, fundamental and preclinical research in NHP (nonhuman primate) models is crucial. Indeed, it is consensually recognized that it is not possible to directly extrapolate results obtained in rodent models to human patients. A large diversity of neurological pathologies should benefit from cellular therapy based on neural differentiation of stem cells. In the context of this special issue of Primate Biology on NHP stem cells, we describe past and recent advances on cell replacement in the NHP model of Parkinson's disease (PD). From the different grafting procedures to the various cell types transplanted, we review here diverse approaches for cell-replacement therapy and their related therapeutic potential on behavior and function in the NHP model of PD.

show abstract

Section: Impact Of the Immune Status Of The Host Brainmentioning

confidence: 90%

Section: Impact Of the Immune Status Of The Host Brainmentioning

confidence: 99%

Transplantation in the nonhuman primate MPTP model of Parkinson's disease: update and perspectives

Wianny

Vezoli

2017

Primate Biol.

View full text Add to dashboard Cite

show abstract

“…Another approach in using MSCs transplantation to improve survival directly, by using them in different models of HD mice it showed improvement in working memory , reduced striatal atrophy [115,116].…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Stem Cells for Neuro-regeneration: State of the Art

Wagih¹,

Elhawary²,

Ellessy³

et al. 2015

BIO

View full text Add to dashboard Cite

Neuroregeneration (NR) is a long-sought medical dream which has intrigued vast research in the past decades. A traditional physiologic dogma that central nervous system does not regenerate has been strongly challenged in the recent years since the advent of the stem cell era. Stem cell research in the regenerative field passes through three main stages. The first stage is the in-vitro experiments which studies the exact molecular and cellular mechanisms underlying stem cell-mediated NR. The second stage is the application of these data in experimental animal settings to provide "proof of concept" of stem cell therapy in animal models. The final step is the translation of these data in pilot clinical trials. In this review, we will try to gather the different data of stem cell-mediated NR from various experimental and clinical researches.

show abstract

“…A recent study investigated the therapeutic effects of the combined transplantation of neuronal-primed ASCs derived from rhesus monkey and adenovirus containing Neurturin (NTN) and tyrosine hydroxylase (TH) (Ad-NTN-TH) into methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned hemi-parkinsonin rhesus monkeys (28). An in vitro study with the use of LIM homeobox transcription factor 1, alpha (LMX1A) and NTN showed that NTN-conditioned medium protected dopaminergic neurons against 1-methyl-4-phenylpyridinium (MPP+) toxicity and the LMX1A-and NTN-infected ASCs showed a dopaminergic differentiation with secreting the dopamine (28).…”

Section: Therapeutic Potential Of Ascs For Parkinson's Disease (Pd)mentioning

confidence: 99%

Therapeutic Potential of Human Adipose-Derived Stem Cells in Neurological Disorders

2014

View full text Add to dashboard Cite

Abstract. Stem cell therapy has been noted as a novel strategy to various diseases including neurological disorders such as Alzheimer's disease, Parkinson's disease, stroke, amyotrophic lateral sclerosis, and Huntington's disease that have no effective treatment available to date. The adipose-derived stem cells (ASCs), mesenchymal stem cells (MSCs) isolated from adipose tissue, are well known for their pluripotency with the ability to differentiate into various types of cells and immuno-modulatory property. These biological features make ASCs a promising source for regenerative cell therapy in neurological disorders. Here we discuss the recent progress of regenerative therapies in various neurological disorders utilizing ASCs.

show abstract

Recovery of behavioral symptoms in hemi-parkinsonian rhesus monkeys through combined gene and stem cell therapy

Cited by 34 publications

References 29 publications

Transplantation in the nonhuman primate MPTP model of Parkinson's disease: update and perspectives

Transplantation in the nonhuman primate MPTP model of Parkinson's disease: update and perspectives

Stem Cells for Neuro-regeneration: State of the Art

Therapeutic Potential of Human Adipose-Derived Stem Cells in Neurological Disorders

Contact Info

Product

Resources

About